ebola
envelop
negativestrand
rna
viru
famili
filovirida
name
filament
morpholog
virion
examin
electron
microscopi
five
speci
ebola
viru
describ
name
region
infect
first
identifi
outbreak
stem
transmiss
ebola
speci
zair
ebolaviru
describ
highest
case
fatal
rate
virul
among
ebola
speci
ebola
viru
presum
zoonot
infect
reservoir
bat
wildlif
popul
episod
infect
human
thu
allow
persontoperson
contact
spread
viru
caus
outbreak
close
contact
infect
individu
especi
via
contamin
bodi
fluid
main
rout
persontoperson
transmiss
ebola
genom
ebola
viru
contain
gene
encod
protein
protein
surfac
ebola
virion
henc
protein
access
circul
antibodi
surfac
glycoprotein
gp
mediat
viru
entri
multipl
differ
cell
type
via
endocytosi
pathogenesi
ebola
viru
diseas
evd
well
understood
like
result
overwhelm
cytopath
damag
due
abil
ebola
viru
replic
throughout
mani
differ
tissu
bodi
dysregul
immun
respons
profound
hypovolemia
commonli
report
symptom
evd
fatigu
fever
weak
myalgia
headach
decreas
appetit
lethargi
although
hemorrhag
complic
predomin
patient
infect
outbreak
report
patient
infect
previou
outbreak
describ
sever
transfus
medicin
review
j
u
r
n
l
h
e
p
g
e
w
w
w
r
e
v
e
w
c
hemorrhag
possibl
due
dissemin
intravascular
coagul
hepatocellular
necrosi
endotheli
disrupt
vascular
permeabl
recent
ebola
outbreak
largest
longest
record
infect
nearli
individu
fatal
rate
approach
area
mani
factor
led
magnitud
veloc
outbreak
west
africa
includ
poor
health
infrastructur
lack
awar
symptom
transmiss
cultur
barrier
popul
densiti
travel
factor
also
led
addit
signific
event
previous
occur
includ
repatri
patient
evd
africa
treatment
center
unit
state
europ
intern
travel
asymptomat
patient
evd
africa
infect
health
care
worker
care
patient
evd
unit
state
europ
realiti
uncertainti
outbreak
forc
heavili
regul
health
care
system
europ
unit
state
develop
polici
procedur
design
protect
patient
hospit
staff
unpreced
circumst
import
lesson
learn
invalu
role
laboratori
play
care
patient
evd
provid
experiment
therapi
support
form
convalesc
blood
product
well
gener
laboratori
result
need
replac
fluid
electrolyt
mainstay
support
care
treatment
center
diseas
control
prevent
guidanc
avail
laboratori
involv
ebola
viru
test
recommend
institut
perform
risk
assess
process
procedur
activ
adjust
practic
need
highestrisk
specimen
includ
patient
known
evd
patient
investig
evd
due
compat
symptom
appropri
epidemiolog
risk
factor
small
potenti
exist
laboratori
personnel
handl
specimen
unbeknownst
contain
ebola
viru
complianc
bloodborn
pathogen
standard
cfr
essenti
part
good
laboratori
practic
main
concern
laboratori
personnel
exposur
infecti
dose
ebola
assumpt
made
design
laboratori
protocol
handl
specimen
ebola
viru
viru
may
persist
day
specimen
bodi
fluid
may
viral
genom
titer
higher
virion
may
infecti
mean
nanolit
blood
expos
mucou
membran
could
potenti
caus
diseas
process
involv
open
tube
centrifug
step
andor
aerosol
potenti
evalu
risk
mitig
step
taken
appropri
certifi
industri
hygienist
help
determin
risk
laboratori
well
potenti
safeti
engin
improv
patient
known
evd
pointofcar
test
locat
biosafeti
hood
minim
specimen
handl
use
success
pointofcar
test
must
compli
clinic
laboratori
improv
amend
clia
regul
cfr
part
addit
test
core
hospit
laboratori
report
specimen
patient
known
evd
long
instrument
close
tube
sampl
capabl
although
avail
initi
outbreak
major
manufactur
decontamin
protocol
sampl
ebola
viru
test
analyz
uniqu
aspect
test
sampl
ebola
viru
must
includ
risk
assess
includ
specimen
transport
infecti
wast
manag
safe
sharp
handl
disinfect
test
surfac
handl
spill
willing
personnel
handl
specimen
although
fluid
ebola
viru
bioterror
potenti
specimen
consid
feder
select
agent
unless
viabl
ebola
viru
intent
isol
fluid
cfr
also
ebola
viru
contain
sampl
safe
transport
follow
requir
depart
transport
categori
infecti
substanc
part
risk
assess
ebola
treatment
center
us
determin
blood
bank
personnel
face
unaccept
risk
sampl
patient
evd
centrifug
uncap
routin
test
autom
analyz
sampl
test
manual
method
requir
cell
washer
step
abo
rh
type
could
instead
perform
use
commerci
avail
reagent
food
drug
administr
fda
approv
slide
agglutin
process
pose
low
risk
aerosol
perform
biosafeti
hood
fig
knowledg
patient
abo
type
help
select
convalesc
nonconvalesc
blood
product
red
blood
cell
rbc
alloor
autoantibodi
test
perform
rbc
unit
serolog
crossmatch
center
provid
univers
compat
blood
product
emerg
releas
basi
patient
known
evd
group
rbc
group
ab
abocompat
plasma
contain
product
type
known
decis
forego
screen
irregular
rbc
antibodi
without
critic
total
patient
treat
europ
unit
state
receiv
nonconvalesc
blood
product
patient
receiv
whole
blood
patient
receiv
plasma
patient
receiv
platelet
advers
event
receiv
nonconvalesc
blood
product
absenc
antibodi
screen
serolog
crossmatch
report
howev
given
small
number
nonconvalesc
blood
transfus
advers
reaction
may
statist
like
improv
blood
transfus
safeti
especi
rbc
transfus
altern
technolog
examin
exampl
cemark
mdmulticard
grifol
barcelona
spain
rapidli
serotyp
rh
k
subgroup
place
drop
patient
blood
onto
card
impregn
antisera
without
centrifug
event
emerg
releas
rbc
transfus
antigencompat
unit
could
select
minim
risk
immunemedi
hemolysi
fig
passiv
immun
experiment
treatment
evd
outbreak
transfus
blood
product
convalesc
survivor
patient
activ
infect
rich
histori
immun
therapi
influenza
measl
polio
sever
acut
respiratori
syndrom
convalesc
blood
product
often
therapi
readili
avail
earli
outbreak
altern
licens
therapi
avail
recognit
convalesc
plasma
cp
potenti
therapi
treat
evd
emerg
shortli
first
descript
ebola
unit
cp
survivor
collect
store
first
evd
cp
bank
highlight
import
challeng
name
variabl
qualiti
plasma
product
term
antibodi
titer
well
transfusiontransmit
diseas
risk
unit
contain
filari
larva
first
use
cp
passiveimmun
therapi
treatment
evd
occur
laboratori
worker
infect
ebola
receiv
dose
cp
surviv
tabl
howev
cours
sever
subsequ
outbreak
record
cp
transfus
chang
ebola
outbreak
center
citi
kikwit
health
care
worker
transfus
convalesc
whole
blood
evd
survivor
patient
activ
diseas
patient
surviv
convalesc
whole
blood
transfus
administ
addit
patient
tabl
recipi
surviv
appear
higher
surviv
rate
observ
nontransfus
patient
outbreak
follow
year
laboratori
studi
use
anim
produc
conflict
result
efficaci
passiv
immun
therapi
treatment
evd
exampl
use
convalesc
blood
transfus
protect
nonhuman
primat
succumb
ebola
infect
contrast
recombin
antibodi
deriv
rna
recov
survivor
outbreak
neutral
activ
antibodi
bound
surfac
gp
also
encourag
studi
show
passiv
transfus
immunoglobulin
seem
protect
nonhuman
primat
mice
ebola
infect
licens
ebola
virusspecif
therapi
medic
evacu
patient
ebola
outbreak
initi
treat
support
critic
care
well
experiment
therapi
consist
monoclon
antiebola
antibodi
antivir
passiv
immun
therapi
zmapp
mapp
biopharmaceut
inc
san
diego
ca
zmab
mapp
biopharmaceut
inc
appear
well
toler
correl
decreas
viral
titer
resolut
symptom
howev
patient
continu
evacu
suppli
monoclon
antibodi
therapi
quickli
deplet
result
evd
treatment
team
turn
ebola
cp
passiv
immun
treatment
especi
given
past
nonhuman
primat
human
report
use
convalesc
blood
product
monoclon
antibodi
ideal
cp
would
obtain
healthi
fulli
recov
donor
ampl
time
perform
appropri
test
safeti
potenc
appropri
safeti
test
would
includ
serolog
nucleic
acid
test
transfusiontransmit
infect
tti
includ
diseas
interest
well
addit
test
need
base
donor
risk
factor
test
plasmodium
risk
unusu
tti
associ
cp
highlight
studi
first
evd
cp
bank
unit
contain
filari
larva
furthermor
ad
layer
protect
provid
pathogen
reduct
techniqu
report
inactiv
ebola
viru
vitro
optim
pathogen
reduct
techniqu
minim
affect
therapeut
potenti
yet
inactiv
parasit
infect
routin
test
addit
transfusionassoci
acut
lung
injuri
trali
mitig
strategi
consid
antihla
antineutrophil
serolog
convalesc
plasma
potenc
would
optim
assess
measur
plasma
neutral
antibodi
level
use
standard
assay
valid
reflect
clinic
benefit
ideal
cp
therapi
would
store
larg
bank
could
support
abomatch
product
highest
potenc
patient
need
unfortun
ideal
ebola
cp
bank
exist
onset
exponenti
growth
phase
outbreak
due
lack
foresight
resourc
evid
efficaci
therefor
cp
evalu
evd
treatment
team
issu
consid
realtim
includ
risk
donor
recipi
cp
vs
potenti
benefit
guidanc
avail
nation
health
author
transfus
servic
outlin
necessari
step
requir
collect
convalesc
whole
blood
ecp
evdrecov
patient
transfus
patient
earli
evd
empir
particular
concern
unit
state
fact
first
potenti
cp
donor
day
discharg
hospit
evd
collect
occur
signific
unknown
regard
cp
time
includ
safe
plasma
collect
volum
donor
determin
qualiti
quantiti
antibodi
level
assess
efficaci
recipi
addit
whether
addit
infecti
diseas
test
need
perform
cp
unknown
time
collect
transfus
ebola
cp
unit
state
pathogenreduct
techniqu
avail
potenti
reduc
transfusiontransmit
diseas
risk
allow
cp
collect
recov
donor
transfus
patient
activ
evd
unit
state
protocol
approv
emerg
investig
new
drug
exempt
fda
includ
appropri
institut
review
board
protocol
clearanc
consent
donor
recipi
investig
new
drug
request
document
ebola
antibodi
titer
product
well
recipi
vital
sign
pretransfus
posttransfus
titer
viral
quantif
first
ebola
cp
donor
unit
state
donat
ml
collect
plasmapheresi
replac
human
albumin
initi
volum
empir
determin
base
donor
safeti
consider
subsequ
process
use
collect
cp
transfus
remain
patient
treat
unit
state
ethic
mani
concern
express
use
investig
therapi
includ
cp
treatment
evd
concern
includ
recruit
donor
surviv
seriou
debilit
infect
potenti
tti
donor
would
otherwis
inelig
unknown
efficaci
cp
inclus
exclus
children
pregnant
woman
access
cp
unknown
risk
addit
cp
shown
effect
therapi
concern
access
cp
would
address
given
limit
suppli
avail
evalu
cp
efficaci
collect
larg
scale
africa
rais
addit
ethic
consider
includ
whether
random
control
trial
appropri
given
high
casefat
rate
case
report
publish
use
cp
evd
fatal
report
tabl
case
report
cp
well
toler
patient
develop
respiratori
complic
evalu
possibl
trali
possibl
attribut
plasma
infus
west
africa
largest
studi
cp
evd
date
perform
nonrandom
compar
studi
examin
use
cp
unknown
antibodi
titer
patient
overal
seriou
advers
reaction
report
cp
use
patient
analyz
surviv
howev
author
conclud
administr
cp
significantli
increas
surviv
compar
histor
control
group
look
studi
combin
suggest
cp
evd
safe
therapi
report
seriou
advers
advent
patient
tabl
although
conclus
regard
safeti
cp
made
avail
data
efficaci
difficult
determin
criterion
standard
gaug
effect
cp
would
random
control
trial
compar
cp
similar
dose
time
administr
antibodi
titer
noncp
plasma
infus
although
standard
dose
time
administr
cp
straightforward
determin
antibodi
titer
standard
assay
avail
even
consid
assay
use
ebola
viru
research
studi
variabl
exist
methodolog
substrat
nomenclatur
make
comparison
difficult
owe
cp
biolog
product
mani
addit
variabl
may
affect
potenti
efficaci
includ
donor
immun
respons
whether
donor
infect
similar
strain
ebola
epitop
recogn
antiebola
antibodi
gp
access
viru
surfac
antigp
antibodi
mechanist
like
neutral
cp
collect
survivor
evd
may
differ
donor
vaccin
ebola
possibl
subset
donor
hightit
neutral
antibodi
measur
clinic
valid
assay
would
yield
cp
measur
efficaci
given
challeng
truli
meaning
conclus
regard
valu
cp
remain
elus
howev
new
outbreak
infect
emerg
especi
high
casefat
rate
cp
continu
use
frontlin
tool
given
favor
safeti
profil
abil
rapidli
deploy
like
improv
widespread
pathogenreduct
avail
